Sahajanand Medical Technologies Share Price & Earnings Call Analysis
- Market cap
- ₹3,497 Cr
- P/E
- 53.56
- ROE
- 11.54%
- Price to sales
- 2.89
- Debt to equity
- 0.50
- Sales growth (5Y)
- 15.52%
- EBITDA margin
- 14.10%
- Net profit margin
- 5.71%
- Sales (last year)
- ₹1,211 Cr
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Equipment & Supplies companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Flat | ₹627 Cr | 21.4 | |
| 2 | 40%+ | Flat | ₹147 Cr | 16.8 | |
| 3 | Q-Line Biotech | 20–40% | Up 2%+ | ₹1,467 Cr | 25.9 |
| 4 | 20–40% | Flat | ₹18,144 Cr | 83.6 | |
| 5 | 20–40% | Flat | ₹173 Cr | 35.0 | |
| 6 | 10–20% | Up 2%+ | ₹170 Cr | 18.8 |
Sign up free to see every company in the sector ranking and track Sahajanand Medical Technologies Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies rankingFinancials of Sahajanand Medical Technologies Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Pros & Cons
Sahajanand Medical Technologies Ltd
Key positives and risks surfaced from the company insights section.
- Company has a low return on equity of 4.58% over last 3 years.
- Company has a low return on equity of 4.58% over last 3 years.
Financials of Sahajanand Medical Technologies Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Jun 2026 | |
|---|---|
| Sales + | 352 |
| Expenses + | 303 |
| Operating Profit | 49 |
| OPM % | 14% |
| Other Income + | 3 |
| Interest | 7 |
| Depreciation | 20 |
| Profit before tax | 24 |
| Tax % | 38% |
| Net Profit + | 15 |
| EPS in Rs | 1.64 |
Financials of Sahajanand Medical Technologies Ltd
Profit & Loss
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 589 | 690 | 902 | 1,025 | 1,210 |
| Expenses + | 539 | 641 | 792 | 896 | 1,040 |
| Operating Profit | 49 | 48 | 110 | 129 | 171 |
| OPM % | 8% | 7% | 12% | 13% | 14% |
| Other Income + | -39 | -19 | 7 | -5 | 8 |
| Interest | 20 | 22 | 19 | 21 | 24 |
| Depreciation | 35 | 38 | 64 | 63 | 74 |
| Profit before tax | -45 | -30 | 33 | 41 | 80 |
| Tax % | 60% | 61% | 122% | 38% | 14% |
| Net Profit + | -72 | -49 | -7 | 25 | 69 |
| EPS in Rs | -8.14 | -5.70 | -1.44 | 2.29 | 7.34 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Sahajanand Medical Technologies Ltd
Balance Sheet
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | |
| Reserves | 325 | 392 | 530 | 556 | |
| Borrowings + | 325 | 386 | 201 | 254 | |
| Other Liabilities + | 191 | 212 | 227 | 274 | |
| Total Liabilities | 849 | 999 | 968 | 1,093 | |
| Fixed Assets + | 203 | 207 | 296 | 288 | |
| CWIP | 60 | 122 | 13 | 6 | |
| Investments | 0 | 0 | 6 | 5 | |
| Other Assets + | 586 | 669 | 652 | 794 | |
| Total Assets | 849 | 999 | 968 | 1,093 |
Financials of Sahajanand Medical Technologies Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 46 | 17 | 41 | 74 | 105 |
| Cash from Investing Activity + | -169 | -154 | -42 | -50 | -130 |
| Cash from Financing Activity + | 212 | 109 | 13 | 6 | -12 |
| Net Cash Flow | 89 | -29 | 12 | 29 | -37 |
| Free Cash Flow | 18 | -76 | 2 | 26 | 17 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 116% | 86% | 55% | 85% | 79% |
Financials of Sahajanand Medical Technologies Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 158 | 125 | 87 | 94 | |
| Inventory Days | 329 | 330 | 397 | 389 | |
| Days Payable | 252 | 213 | 129 | 152 | |
| Cash Conversion Cycle | 235 | 242 | 355 | 331 | |
| Working Capital Days | 122 | -9 | 69 | 60 | |
| ROCE % | 1% | 10% |
Continue your research
Others in Healthcare Equipment & Supplies this season
- Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
- Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
- Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
- Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec